Benzinga · Feb 19, 2026
AM
NASDAQ · AMIX
Autonomix Medical, Inc. Common Stock
Healthcare · Medical - Devices
$4.21
Down-$0.15 (-3.56%)
Updated Sep 16, 2026, 6:53 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.26M
- P/E ratio
- -0.23
- Dividend yield
- 0.00%
- 52-week range
- $0.20 – $24.68
- Volume
- 128.1K
- Avg. volume
- 3.33M
Price performance
AMIX price history
1M range · 20 trading sessions · Daily adjusted prices
AMIX closed at $4.21 after 20 trading sessions, down 31.77% for the selected period.
- Last close
- $4.21
- Period change
- -31.77%
- Period low
- $4.21
- Period high
- $7.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $4.26 | $4.45 | $4.13 | $4.21 | 128.1K |
| Sep 14, 2026 | $4.30 | $4.42 | $4.23 | $4.33 | 55K |
| Sep 11, 2026 | $4.39 | $4.52 | $4.302 | $4.37 | 56.66K |
| Sep 10, 2026 | $4.48 | $4.51 | $4.32 | $4.385 | 86.03K |
| Sep 9, 2026 | $4.60 | $4.6661 | $4.40 | $4.57 | 87.92K |
| Sep 8, 2026 | $4.47 | $4.75 | $4.47 | $4.58 | 79.3K |
| Sep 4, 2026 | $4.59 | $4.68 | $4.4437 | $4.59 | 66.81K |
| Sep 3, 2026 | $4.475 | $4.81 | $4.31 | $4.68 | 197.94K |
| Sep 2, 2026 | $4.65 | $4.6808 | $4.39 | $4.50 | 108.46K |
| Sep 1, 2026 | $4.67 | $4.80 | $4.53 | $4.74 | 126.76K |
| Aug 31, 2026 | $5.20 | $5.20 | $4.66 | $4.83 | 362.9K |
| Aug 28, 2026 | $5.37 | $5.61 | $5.08 | $5.32 | 314.75K |
| Aug 27, 2026 | $6.21 | $6.29 | $5.62 | $5.63 | 362.89K |
| Aug 26, 2026 | $6.83 | $7.30 | $6.3109 | $6.38 | 1.44M |
| Aug 25, 2026 | $7.61 | $9.99 | $7.145 | $7.19 | 28.62M |
| Aug 24, 2026 | $5.24 | $5.59 | $4.9701 | $5.37 | 15.6M |
| Aug 21, 2026 | $5.19 | $5.87 | $5.19 | $5.27 | 109.84K |
| Aug 20, 2026 | $5.79 | $5.97 | $5.14 | $5.27 | 176.96K |
| Aug 19, 2026 | $6.01 | $6.19 | $5.79 | $5.91 | 82.98K |
| Aug 18, 2026 | $6.18 | $6.27 | $5.75 | $6.17 | 105.76K |
Latest AMIX news
The latest Smart Investors Daily articles mentioning AMIX.
Stock researchCompany · Overview
AMIX research
Overview
Company profile and research snapshot.
Company profile
Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 17, 2026 | Maxim Group | Buy | — |
| Apr 29, 2025 | Maxim Group | Buy | — |
| Sep 3, 2024 | Ladenburg Thalmann | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 26, 2025
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth
THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Brad Hauser, President and CEO of Autonomix, discussed two key areas that are shaping the Company’s path forward: protecting the strength of its platform through intellectual property,
globenewswire.com · Nov 26, 2025
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth
THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company's website. For the segment, Brad Hauser, President and CEO of Autonomix, discussed two key areas that are shaping the Company's path forward: protecting the strength of its platform through intellectual property, and exploring new opportunities beyond its initial target, pancreatic cancer, into potential future targets in the cardiovascular space, pulmonary space as well as chronic pain.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
